The recent acquisition of Neogen’s genomics business strengthens Zoetis’s precision animal health pipeline and aligns with its strategic focus on high-margin biotech solutions. Technical indicators near support levels suggest a potential upside consolidation, bolstering bullish sentiment.

While health‑care stocks pulled back later in the day, Zoetis’s deal counters pressure with a clear growth catalyst in genomics, balancing overall market sentiment. Thus the broader market trend remains neutral, with the acquisition easing downside risk.

The genomics purchase expands Zoetis’s product portfolio, potentially reducing future revenue volatility and enhancing long‑term value; however, integration costs pose short‑term risk.

Moving above the 20‑period simple moving average on a 4‑hour chart, the stock shows a bullish crossover that supports a short‑term upward bias.